 |
 |
 |
Welcome to ARONORA
Business Area
ARONORA, LLC is a unique start-up biotechnology company focusing on
fundamentally new concepts to develop biological blood clot treatment
drugs that do not cause bleeding.
Our product pipeline includes the following two novel drug candidates:
WE-thrombin- is a proprietary injectable thrombus-specific antithrombotic
agent – a selective thrombomodulin (TM)-dependent protein C activator
(PCA) enzyme. The lead PCA molecule to be developed for sale is the
recombinant double-mutant human thrombin analog (WE-thrombin) that
contains two amino acid substitutions: Trp215Ala and Glu217Ala. WE-
thrombin is intended for profibrinolytic, neuroprotective, and antithrombotic
treatment of patients with acute stroke. The two immediate advantages of
using WE-thrombin in place of tPA for the causal treatment of ATIS are
better safety and lower dose. Both attributes typically translate into
significant commercial advantages. The only competing product, tPA, has
not gained wide market acceptance, primarily due to its dangerous
bleeding side effects in ATIS. Since WE-thrombin acts through generation
of APC, and APC protects the brain from the direct toxicity and hemorrhagic
effects of tPA, WE-thrombin will be evaluated both as a stand-alone
treatment and as an add-on therapy to tPA. (WE for stroke video)
AXIMAB- is an anti-factor XI monoclonal antibody. AXIMAB is specific for
thrombosis because it inhibits blood coagulation inside blood vessels
without measurable effect on the coagulation of blood in tissue-factor
contaminated wounds. A single dose of AXIMAB anticoagulates primates
for more than a week. Inhibition of factor XI has more potent antithrombotic
effects than high dose heparin or aspirin, but it has no measurable
bleeding side effects. Since knockout of the factor XI gene improves the
survival of untreated bacterial sepsis in mice, AXIMAB is being developed
for use in severe sepsis-associated coagulopathy. (AXIMAB article in Blood)
FINANCING AND VALUE PROPOSITION:
We have received a Fast-Track (Phase I/II) SBIR from the National Heart,
Lung & Blood Institute for the development of WE-thrombin, as well as an
Advanced Technology Phase I SBIR from the National Institute of Allergy &
Infectious Diseases to support development of our factor XI inhibitor for
sepsis. We are also seeking private investment of up to $5M per drug
candidate for building value through product development. Several-fold ROI
is expected following IPO, or merger/acquisition by large pharma
companies within 4 years. The NIH and AHA have invested $5M in related
basic innovative research to date.
Business Area
ARONORA, LLC is a unique start-up biotechnology company focusing on
fundamentally new concepts to develop biological blood clot treatment
drugs that do not cause bleeding.
Our product pipeline includes the following two novel drug candidates:
WE-thrombin- is a proprietary injectable thrombus-specific antithrombotic
agent – a selective thrombomodulin (TM)-dependent protein C activator
(PCA) enzyme. The lead PCA molecule to be developed for sale is the
recombinant double-mutant human thrombin analog (WE-thrombin) that
contains two amino acid substitutions: Trp215Ala and Glu217Ala. WE-
thrombin is intended for profibrinolytic, neuroprotective, and antithrombotic
treatment of patients with acute stroke. The two immediate advantages of
using WE-thrombin in place of tPA for the causal treatment of ATIS are
better safety and lower dose. Both attributes typically translate into
significant commercial advantages. The only competing product, tPA, has
not gained wide market acceptance, primarily due to its dangerous
bleeding side effects in ATIS. Since WE-thrombin acts through generation
of APC, and APC protects the brain from the direct toxicity and hemorrhagic
effects of tPA, WE-thrombin will be evaluated both as a stand-alone
treatment and as an add-on therapy to tPA. (WE for stroke video)
AXIMAB- is an anti-factor XI monoclonal antibody. AXIMAB is specific for
thrombosis because it inhibits blood coagulation inside blood vessels
without measurable effect on the coagulation of blood in tissue-factor
contaminated wounds. A single dose of AXIMAB anticoagulates primates
for more than a week. Inhibition of factor XI has more potent antithrombotic
effects than high dose heparin or aspirin, but it has no measurable
bleeding side effects. Since knockout of the factor XI gene improves the
survival of untreated bacterial sepsis in mice, AXIMAB is being developed
for use in severe sepsis-associated coagulopathy. (AXIMAB article in Blood)
FINANCING AND VALUE PROPOSITION:
We have received a Fast-Track (Phase I/II) SBIR from the National Heart,
Lung & Blood Institute for the development of WE-thrombin, as well as an
Advanced Technology Phase I SBIR from the National Institute of Allergy &
Infectious Diseases to support development of our factor XI inhibitor for
sepsis. We are also seeking private investment of up to $5M per drug
candidate for building value through product development. Several-fold ROI
is expected following IPO, or merger/acquisition by large pharma
companies within 4 years. The NIH and AHA have invested $5M in related
basic innovative research to date.